Nivolumab in nonsquamous non-small-cell lung cancer. Borghaei H,Brahmer J. The New England Journal of Medicine . 2016Borghaei H, Brahmer J. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2016;374:493-4.Nivolumab in nonsquamous non-small-cell lung cancer. Ha...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015). One of the first phase III trials to confirm superiority of second-line immunotherapy compared with chemotherapy after disease progression on first-line chemotherapy ...
Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways. The three most common forms of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcino...
Non-small cell lung cancer is the most common kind of lung cancer. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. nsclctagrissoegfralklungalectinibalimtagilotrifpemetrexedexoncrizotinibalecensapennellmutationentrectiniblorlatinibim...
Therapeutics and Clinical Risk Management Dovepress open access to scientific and medical research Open Access Full Text Article review Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer This article was published in the following Dove Press journal: Therapeutics and Clinical ...
Non-small cell lung cancerVEGFRPD-L1EGFRSquamous non-small (NSCLC) has always been characterized by a limited number of therapeutic options and by the lack of actionable biomarkers compared to its non-squamous counterpart. Recent clinical trials have led to the approval of new anti-neoplastic ...
Lung Cancer: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Review Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer This article was published in the following Dove Press journal: Lung Cancer:Targets ...
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL PURPOSE: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, improves survival when combined with carboplatin/paclitaxel for...
et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018). Article CAS PubMed Google Scholar Gettinger, S. et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the...